These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 37792132)

  • 21. Inclisiran: A Review in Hypercholesterolemia.
    Frampton JE
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol.
    Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW
    Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a).
    Katsiki N; Vrablik M; Banach M; Gouni-Berthold I
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
    Warden BA; Duell PB
    J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
    Mohamed F; Botha TC; Raal FJ
    Curr Opin Lipidol; 2021 Aug; 32(4):213-218. PubMed ID: 33883446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
    Sinning D; Landmesser U
    Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease.
    Albosta MS; Grant JK; Taub P; Blumenthal RS; Martin SS; Michos ED
    Vasc Health Risk Manag; 2023; 19():421-431. PubMed ID: 37434791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention.
    Gaine SP; Quispe R; Patel J; Michos ED
    Curr Cardiovasc Risk Rep; 2022 Sep; 16(9):69-78. PubMed ID: 36213094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
    Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent.
    Giordano S; Polimeni A; Esposito G; Indolfi C; Spaccarotella C
    Curr Opin Lipidol; 2023 Aug; 34(4):133-140. PubMed ID: 36924354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials.
    Koenig W; Conde LG; Landmesser U; Leiter LA; Ray KK; Schwartz GG; Wright RS; Han J; Raal FJ
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):493-503. PubMed ID: 36550348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis.
    Mohamed F; Mansfield BS; Raal FJ
    Curr Atheroscler Rep; 2022 Dec; 24(12):959-967. PubMed ID: 36367663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.
    Alhomoud IS; Talasaz A; Mehta A; Kelly MS; Sisson EM; Bucheit JD; Brown R; Dixon DL
    Pharmacotherapy; 2023 Oct; 43(10):1051-1063. PubMed ID: 37464942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
    Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia.
    Wiggins BS
    J Cardiovasc Pharmacol; 2021 Nov; 78(5):e631-e640. PubMed ID: 34738550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Primary disorders of lipid metabolism: their place in current dyslipidemia guidelines and treatment innovations].
    Klose G; Gouni-Berthold I; März W
    Inn Med (Heidelb); 2023 Sep; 64(9):895-906. PubMed ID: 37280381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.
    Luo F; Das A; Khetarpal SA; Fang Z; Zelniker TA; Rosenson RS; Qamar A
    Trends Cardiovasc Med; 2024 May; 34(4):215-222. PubMed ID: 36746257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.